JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, J. H.
Right arrow Articles by Smith, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, J. H.
Right arrow Articles by Smith, P. C.

Influence of renal failure in rats on the disposition of salicyl acyl glucuronide and covalent binding of salicylate to plasma proteins

JH Liu, RS Malone, H Stallings and PC Smith

School of Pharmacy, University of North Carolina at Chapel Hill, USA.

Many acyl glucuronides are labile, reactive and form covalent adducts with proteins. In the present experiment, the stability of salicyl acyl glucuronide (SAG), its reactivity with serum albumin in vitro and the influence of renal failure in rats on the disposition of SAG and covalent binding of salicylate (SA) to rat plasma proteins were investigated. In vitro studies showed that SAG was hydrolyzed to SA or undergoes isomerization to positional isomers. The half-life of SAG was 1.3 hr in 0.15 M phosphate buffer at pH 7.4 and 37 degrees C, but the stability of its isomers was much greater with an apparent half-life of 19 hr. Incubation of SAG in solutions of human serum albumin revealed the formation of covalent adducts with the protein, with maximal binding of 2.8% of total SA equivalents added to the solution. For in vivo studies, one group of rats was administered 5 mg/kg of uranyl nitrate i.p. to induce renal failure. After administration of 100 mg/kg of SA i.v., the AUC 0-26 hr of SAG in rats with renal failure was 9 times higher than that observed in control rats. The apparent clearance of SA decreased from 64 +/- 21 ml/hr in control rats 28 +/- 8.7 ml/hr in rats with renal failure. The level of SA covalent adducts with plasma proteins reached about 0.5 ng/mg of protein in control rats, whereas in rats with renal failure the binding was increased significantly and achieved an average peak concentration of 18 ng/mg of protein when measured 26 hr after dosing. The data indicate that reactive SAG can accumulate in renal failure which then increases covalent addition of SA to proteins. Such binding may have a role in enhancing the potential for toxicity of acidic drugs such as SA in renal disease.

Volume 278, Issue 1, pp. 277-283, 07/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. T. Stern, M. N. Tallman, K. K. Miles, J. K. Ritter, and P. C. Smith
Androgen Regulation of Renal Uridine Diphosphoglucuronosyltransferase 1A1 in Rats
Drug Metab. Dispos., September 1, 2008; 36(9): 1737 - 1739.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Y. J. Moon, A. K. Lee, H. C. Chung, E. J. Kim, S. H. Kim, D. C. Lee, I. Lee, S. G. Kim, and M. G. Lee
EFFECTS OF ACUTE RENAL FAILURE ON THE PHARMACOKINETICS OF CHLORZOXAZONE IN RATS
Drug Metab. Dispos., June 1, 2003; 31(6): 776 - 784.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Ebner, G. Heinzel, A. Prox, K. Beschke, and H. Wachsmuth
Disposition and Chemical Stability of Telmisartan 1-O-Acylglucuronide
Drug Metab. Dispos., October 1, 1999; 27(10): 1143 - 1149.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics.